Sana Biotechnology, Inc.

Two and a half months after its first US Food and Drug Administration approval for Incyte Corp.-partnered Niktimvo (axatilimab-csfr) in chronic graft-versus-host disease (GVHD), Syndax Pharmaceuticals

Pfizer is progressing its 10-program partnership with Flagship Pioneering , opting to explore new targets in cardiovascular and renal disease with Flagship-founded somatic genomics company Quotient.

Biomedtracker’s latest report on biopharmaceutical company fundraising shows a 25.1% decline in year-over-year dollars raised, from $17.5bn in the fourth quarter of 2022 to $13.1bn in Q4 of 2023. Foll

Sana has won over investors with new early data from its off-the-shelf CAR-T candidate, SC291, the results suggesting its ‘hypoimmune modified’ design might overcome some of field’s long-standing obs